Delta Lloyd’s BioMarin Pharmaceuticals BMRN Stock Holding History

Delta Lloyd’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$1.54M	Hold	16,975	–	–	0.04%	314
2017 Q1	$1.49M	Hold	16,975	–	–	0.04%	306
2016 Q4	$1.41M	Buy	16,975 +5,698	+51%	+$490K	0.04%	305
2016 Q3	$1.04M	Hold	11,277	–	–	0.03%	388
2016 Q2	$877K	Hold	11,277	–	–	0.03%	412
2016 Q1	$930K	Hold	11,277	–	–	0.03%	388
2015 Q4	$1.18M	Buy	11,277 +340	+3%	+$35.5K	0.04%	315
2015 Q3	$1.15M	Hold	10,937	–	–	0.04%	316
2015 Q2	$1.5M	Buy	10,937 +3,679	+51%	+$456K	0.05%	276
2015 Q1	$904K	Buy	7,258 +1,467	+25%	+$155K	0.03%	319
2014 Q4	$524K	Hold	5,791	–	–	0.02%	432
2014 Q3	$418K	Hold	5,791	–	–	﹤0.01%	476
2014 Q2	$360K	Hold	5,791	–	–	0.01%	491
2014 Q1	$395K	Buy	5,791 +1,664	+40%	+$123K	0.01%	424
2013 Q4	$290K	Sell	4,127 -82,000	-95%	-$5.57M	0.01%	486
2013 Q3	$6.22M	Sell	86,127 -33,129	-28%	-$2.2M	0.24%	95
2013 Q2	$6.65M	Buy	+119,256	New	+$7.43M	0.26%	89

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Delta Lloyd's BMRN Position: Q2 2017 in Review

Delta Lloyd held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2017 at 16,975 shares worth $1.54M. The position accounts for 0.04% of the portfolio, ranked #314.

Delta Lloyd first reported a position in BMRN in Q2 2013 and has held it in 17 quarters since. The position peaked at $6.65M in Q2 2013. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

Delta Lloyd held 16,975 shares of BioMarin Pharmaceuticals worth $1.54M as of Q2 2017.
Delta Lloyd left its BioMarin Pharmaceuticals share count unchanged in Q2 2017.
BioMarin Pharmaceuticals made up 0.04% of Delta Lloyd's portfolio in Q2 2017, its #314 holding.
Delta Lloyd first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Delta Lloyd's BioMarin Pharmaceuticals position peaked at $6.65M in Q2 2013.
426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Delta Lloyd's 13F filing for Q2 2017, filed 9 Aug 2017.